| abstract |
It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect on inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a neuroprotective effect, and anti-allergic effect, and anti-arteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease which involves the step of qualitatively or quantitatively measuring the degree of the binding of a test compound to a 67 kDa laminin receptor, and judging that the test compound is a drug having an effect of inhibiting cell proliferation, and angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a neuroprotective effect, and anti-allergic effect, and anti-arteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease in the case where it is found out by the results of the measurement that the test compound binds to the 67 kDa laminin receptor, and a drug obtained thereby. |